Sign in

CIK 0001789972

  • Non-accelerated filer
  • Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813879991
Phone
+1 617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 3 Insider Initial Statement of Ownership
  4. 3 Insider Initial Statement of Ownership
  5. 4 Grant or award Chief Development Officer acquired 28,500 shares (grant or award)
  6. 4 Grant or award Chief Legal Officer acquired 22,500 shares (grant or award)
  7. 4 Grant or award Baeuerle Patrick acquired 37,500 shares (grant or award)
  8. 4 Grant or award Zawel Leigh acquired 32,500 shares (grant or award)
  9. 4 Grant or award Acting Chief Business Officer acquired 16,500 shares (grant or award)
  10. 4 Grant or award Chief Financial Officer acquired 37,500 shares (grant or award)
  11. 4 Other disposition 10% owner disposed of 1,187,734 shares (other)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Derivatives Options or other derivatives
  14. 3 Insider Initial Statement of Ownership
  15. 4 Open-market sale Michaelson Jennifer sold 4,000 shares at an average $21.42 ($85,669)
  16. 4 Open-market sale Chief Financial Officer sold 8,000 shares at $25.00 ($200,000)
  17. 4 Open-market sale Zawel Leigh sold 19,574 shares at $25.00 ($489,350)
  18. 4 Open-market sale Zawel Leigh sold 1,079 shares at $25.00 ($26,975)
  19. 4 Open-market sale Michaelson Jennifer sold 4,000 shares at an average $24.51 ($98,048)
  20. 4 Open-market sale Zawel Leigh sold 7,468 shares at $25.16 ($187,895)

Page 10 of 13 · 253 filings